ISSN 2043-8087
Journal of Experimental Psychopathology
 Volume 4, Issue 1, 64-77, 2013
Abstract  E-mail Abstract   Article Purchase as PDF 
Return to Issue List 
Assessing the Boundaries of Symptom Over-Reporting Using the Structured Inventory of Malingered Symptomatology in a Clinical Schizophrenia Sample: Its Relation to Symptomatology and Neurocognitive Dys

Maarten J.V. Peters(a),(b), Marko Jelicic(a), Steffen Moritz(c), Marit Hauschildt(c) & Lena Jelinek(c)
(a) Department of Clinical Psychological Science, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands
(b) The Maastricht Forensic Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands
(c) University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martinistrasse 52, 20246 Hamburg, Germany

Volume 4, Issue 1, 2013, Pages 64-77

The rationale behind symptom over-reporting tests is that patients with no intention to feign symptoms will perform below a specific cut-off point because of the bizarreness of the symptoms presented. Given this rationale, very few studies have attempted to determine the specificity of these measures, i.e., whether clinical psychiatric patients would not endorse these exaggerated symptoms. In the present studies, endorsement of bizarre and atypical symptoms in such patients was explored. In two studies, the Structured Inventory of Malingered Symptomatology (SIMS) was administered to a sample of schizophrenia patients (study 1 n = 18; study 2: n = 23) and healthy controls (study 1 n = 19; study 2 n = 24) together with a neurocognitive test (Wisconsin Card Sorting Test; study 1) and schizophrenia symptomatology indices (study 2; PANSS and PSYRATS). Results from both studies indicate that serious psychopathology may significantly interfere with symptom validity performance measures: According to the SIMS cut-off criteria, symptom over-reporting would be present in almost 30 percent of the schizophrenia patients (28% in study 1 and 30% in study 2) but not in the healthy sample. Furthermore, SIMS scores in the schizophrenia sample explained a significant amount of variance in neurocognitive performance (study 1) and was positively correlated with PANSS positive symptomatology (study 2; r = .58, p < .01), PANSS distress (study 2; r = .50, p < .05), and PSYRATS hallucination and total scores (r = .60, p < .01 and r = .75 p < .001). Consequently, it is discussed that cut-off points may need adjustment in psychotic patients with positive symptomatology when litigation is clearly not an issue.

Table of Contents
Study 1
SIMS total score and neurocognitive dysfunction
Moderating variables
Study 2
Socio-demographic and background variables
SIMS total score in relation to symptomatology
Moderating variables
Additional analyses
Discussion and Conclusions

Correspondence to
Maarten J.V. Peters, Maastricht University, Faculty of Psychology and Neuroscience, Department of Clinical Psychological Science, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.

schizophrenia, neurocognitive dysfunction, symptom validity, symptomatology

Received 7 Sep 2011; Revised 1 Mar 2012; Accepted 1 Mar 2012; In Press 4 Mar 2013

Bookmark and Share

Related articles by AUTHORS
None Found

Related articles by KEYWORDS
None Found

© Copyright 2009-2016 Textrum Ltd . All rights reserved. Published in the UK. - Contact Us Advertise | Privacy Policy | Terms of Use